Investment Rating - The industry investment rating is "Outperform" [37] Core Insights - AbbVie reported total revenue of $56.334 billion in 2024, a year-on-year increase of 3.7%, with R&D investment rising by 66.7% to $12.791 billion [4][9] - The sales forecast for Skyrizi and Rinvoq has been raised, with combined sales expected to exceed $27 billion by 2027, including over $17 billion from Skyrizi and over $10 billion from Rinvoq [4][27] - AbbVie is gradually reducing its reliance on Humira, which saw a 37.6% decline in sales to $8.993 billion in 2024 due to patent expiration and competition from biosimilars [18] Summary by Sections Part 1: 2024 Financial Overview and Key Events - AbbVie achieved a net revenue of $56.334 billion in 2024, with significant growth in its immunology and oncology segments [9][10] - The company advanced five projects into regulatory approval stages and submitted four projects for regulatory review in 2024 [11][13] Part 2: Core Product Sales Analysis - Skyrizi and Rinvoq generated revenues of $11.718 billion and $5.971 billion respectively, marking increases of 50.9% and 50.4% [18] - The oncology segment saw stable growth with Venclexta reaching $2.583 billion in sales, a 12.9% increase [20] Part 3: 2025 Pipeline Milestones - In 2025, AbbVie expects two drugs to receive regulatory approval and plans to submit four regulatory decisions and readout three Phase III data [24] - Key regulatory submissions include Venclexta for high-risk MDS and Rinvoq for giant cell arteritis [24] Part 4: 2025 Financial Outlook - AbbVie anticipates earnings per share to reach between $12.12 and $12.32, with a strong sales outlook for Skyrizi and Rinvoq [27] Part 5: Investment Recommendations - The report suggests focusing on domestic companies targeting the IL-23 pathway, such as Innovent Biologics and Hansoh Pharmaceutical, due to the growth potential of Skyrizi [32]

Investment Rating - The report suggests a cautious outlook for the US stock market, predicting continued volatility and a downward trend until late March or early April 2025, with a focus on sectors such as healthcare, consumer services, traditional telecommunications, and utilities [6][14]. Core Insights - The US stock market is facing significant pressure due to uncertainties surrounding tariffs and economic indicators that have fallen short of expectations, leading to a potential rotation of funds out of the market [6][14]. - The report highlights the resilience of the US labor market, as indicated by an increase in job vacancies and resignation rates, which may alleviate recession fears [6][26]. - The copper industry is expected to see price increases due to anticipated tariffs on imports, which could create supply shortages in the US market [14][26]. - The pharmaceutical sector is poised for valuation recovery, supported by government policies aimed at optimizing drug pricing and promoting innovative drug development [14][19]. Summary by Sections US Market Dynamics - The US stock market has retraced all gains since the Federal Reserve's rate cuts in September 2024, with consumer discretionary and industrial sectors facing significant impacts from tariff uncertainties [6][14]. - Major US indices experienced declines, with the Dow Jones dropping 1.14% and the S&P 500 down 0.76% [8][10]. European Market Dynamics - European markets also faced declines, with the Stoxx 600 index down 1.7%, driven by concerns over economic growth and tariff announcements from the US [10][14]. Asian Market Dynamics - The Asian markets showed mixed results, with the Thai market gaining 0.9%, while other markets like the Philippines and Singapore experienced declines [21][22]. Sector Performance - In the US, the industrial sector was notably affected by tariff announcements, leading to a 1.54% drop in the industrial index [10][14]. - In the Hong Kong market, sectors such as consumer goods and technology showed positive performance, with notable gains in companies like China Resources Beverage [10][11]. Individual Company Insights - Snowflake reported better-than-expected revenue performance, with AI products contributing to growth, and the company is viewed positively for its long-term investment potential [8][19]. - The copper sector is recommended for investment due to expected price increases driven by tariff-related supply constraints, with specific companies like Zijin Mining and Luoyang Molybdenum highlighted [14][19].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry as of March 1, 2025 [1]. Core Insights - The report highlights the performance of the innovative drug sector in both A-shares and Hong Kong stocks, with a total of 81 stocks rising and 27 falling during the fourth week of February 2025. The top gainers included Chuangsheng Group-B (+92.13%), Beihai Kangcheng-B (+51.97%), and Deqi Pharmaceutical-B (+39.51). Conversely, the largest declines were seen in WuXi AppTec-B (-15.35%), Hualing Pharmaceutical-B (-12.77%), and Yiming Oncology-B (-4.46) [2][20]. - The A-share innovative drug sector experienced a slight decline of 0.05%, underperforming the CSI 300 index by 0.26 percentage points, while the biopharmaceutical sector fell by 1.71%. Over the past six months, the A-share innovative drug sector has cumulatively decreased by 0.06%, outperforming the CSI 300 index by 7.71 percentage points, and the biopharmaceutical sector has increased by 1.57% [22]. - The Hong Kong innovative drug sector saw an increase of 3.22%, outperforming the Hang Seng Index by 1.02 percentage points, with the Hang Seng Healthcare sector rising by 0.52%. In the last six months, the Hong Kong innovative drug sector has decreased by 3.71%, but has outperformed the Hang Seng Index by 18.1 percentage points, while the Hang Seng Healthcare sector has increased by 9.73% [24]. Summary by Sections Domestic Innovative Drug Progress - In February, eight new drugs were approved for market launch in China, with no new drug approvals or new indications reported in the last week [4][41]. Overseas Innovative Drug Progress - In February, the U.S. approved 10 NDA applications and 6 BLA applications. In the last week, one NDA and one BLA were approved. No new drugs were approved in Europe or Japan during February [5][34][38]. Global Innovative Drug Transactions - A total of 12 significant transactions occurred globally, with four transactions disclosing amounts. Notable agreements included Magnet Biomedicine with Lill for $1.29 billion, and Bridgene Biosciences with Takeda Pharmaceuticals for $816 million [6]. Market Performance - The XBI index fell by 1.49% in the last week, with a cumulative decline of 9.88% over the past six months [3][25]. Innovative Drug Sales Performance - Sales figures for innovative drugs in 2023 showed significant growth, with Tirzepatide (Mounjaro) achieving $5.163 billion in sales (+970.1%), and Semaglutide (Ozempic) generating $13.889 billion (+60%) in sales for its diabetes indication [19].

医药| 2025 年 2 月 18 日 医药| 行业点评 重点推荐年报预期良好的企业 2025 年 1 月全球与中国医疗融资呈回暖态势 根据著名医疗数据库动脉网统计，2025年1月全球医疗健康行业披露的融资总额为80.04亿美元， 较 12 月环比上升 100.5%。中国市场 1 月披露的医疗健康行业融资总额为 9.56 亿美元，较 11-12 月 分别上升 90.8%与 71.3%。全球医疗健康行业的融资总额在 2022-23 年大幅下降后，2024 年已同比 回升 1.4%，因此 1 月是在持续回暖。中国的医疗健康行业融资总额 2022 年后持续下滑，2024 年 仍同比下降 33.0%，回暖速度慢于全球。虽然如此，2025 年 1 月中国市场的医疗健康行业融资情 况也呈回暖状态。 国家医保局将积极推进医保跨省共济，将一定程度利好药品销售 根据国家医保局新闻，截止 2 月 4 日，广东、上海、江苏、西藏等 14 个省、自治区和直辖市的 117 个统筹地区（地级以上行政区及一定人口以上的县或市）已开通医保跨省共济。国家医保局 2 月 14 日再次指出将继续推进跨省共济的普及，2025 年底前 90%以上的统 ...

行业评级 推荐（维持） 行业周报 | 医药生物 证券研究报告 报告日期 2025 年 02 月 17 日 相关研究 【兴证医药】AI 有望赋能医疗领域，继 续看好创新药+创新药产业链——医药行 业周报（2025.2.3-2025.2.7）- 2025.02.11 【兴证医药】医药板块持仓降至历史低 位、继续看好创新药+创新药产业链—— 兴证医药 2025 年 2 月投资月报- 2025.02.05 【兴证医药】医保丙类目录推进中，有 望进一步提升创新药可及性——医药行 业周报（2025.1.13-2025.1.17）- 2025.01.20 分析师：孙媛媛 S0190515090001 sunyuanyuan@xyzq.com.cn 分析师：黄翰漾 S0190519020002 huanghanyang@xyzq.com.cn | 年 2 | 表 1、2025 年 2 | 月 10 | 日-2025 | | 月 14 | | 日医药板块个股涨幅前 5 | 和跌幅前 5 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | ...

以下文章来源于天天IPO ，作者周佳丽 天天IPO . 投资界（PEdaily.cn）旗下，专注IPO动态 赴港二次上市潮。 作者 I 周佳丽 报道 I 投资界-天 天IPO 投资界-天天IPO获悉，恒瑞医药正式向港交所递交上市申请。这意味着，2 0 0 0年在A股 上市、市值28 00亿元的医药龙头正式启动赴港IPO了，也许很快将实现"A+H"两地上 市。 说起恒瑞医药，不得不提到灵魂人物——孙飘扬。来自江苏淮安，孙飘扬一度被国内冠 以"药神"称号，他一手将不知名的小药厂做到中国医药界巨头，恒瑞医药巅峰市值一度 冲破6 0 00亿元。如今，恒瑞医药赴港上市，66岁的孙飘扬有望再一次IPO敲钟。 而其妻子钟慧娟掌舵的翰森制药早已于20 1 9年在港交所IPO上市，最新市值超9 00亿港 元。 66岁大佬，又要IPO敲钟了 故事从孙飘扬说起。 1 9 5 8年生于江苏淮安金湖，孙飘扬1 98 2年从中国药科大学化学制药专业毕业。多年后的 2 0 0 4年，他又获得中国南京大学有机化学博士学位。 本科毕业后，孙飘扬便被分配到连云港制药厂，也就是恒瑞医药的前身，担任技术员，从 事配料、计算等工作。后来由于勤奋踏实， ...

Core Insights - The study published in the journal "Kidney Medicine" demonstrates the effectiveness of the peptide, Pemolizumab, in treating EPO-induced Pure Red Cell Aplasia (PRCA) patients, indicating a promising innovative solution for this rare but serious complication [1] Group 1: Research Findings - The research led by Professor Fan Qiuling from Shanghai Jiao Tong University School of Medicine shows that Pemolizumab can effectively treat EPO-induced PRCA in a non-dialysis Chinese patient with type 1 diabetes nephropathy [1] - The study confirmed Pemolizumab's potential in treating EPO-induced PRCA, as evidenced by significant improvements in hemoglobin levels and anemia symptoms without notable adverse reactions [1] Group 2: Clinical Implications - The findings provide a new safe, effective, and convenient treatment option for EPO-induced PRCA, addressing a critical need in clinical practice [1] - The patient's clinical course, reticulocyte count reduction, and bone marrow biopsy results were consistent with EPO treatment-induced PRCA, reinforcing the study's conclusions [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [3] Core Views - The company has successfully completed several significant license-out transactions in the oral small molecule GLP-1 space, including a deal with Merck that involves an upfront payment of $112 million and potential milestone payments totaling up to $1.9 billion [3][14] - The company's innovative pipeline is robust, and its global expansion is progressing smoothly, leading to a maintained "Buy" rating [4] Financial Forecasts - The company is expected to achieve total revenues of RMB 119.07 billion, RMB 133.28 billion, and RMB 148.36 billion for the years 2024, 2025, and 2026 respectively [4][5] - Net profits are projected to be RMB 40.10 billion, RMB 41.80 billion, and RMB 43.17 billion for the same years, with corresponding P/E ratios of 25, 24, and 23 times [4] - The company reported a significant increase in innovative drug sales, with a revenue of RMB 50.32 billion in the first half of 2024, representing a year-on-year growth of 80.6% [15] Market Performance - The closing price of the company's stock is HKD 17.80, with a one-year high of HKD 22.80 and a low of HKD 11.18 [2] - The total market capitalization is approximately HKD 105.65 billion [2]

Investment Rating - Maintain BUY rating for Hansoh Pharma with a target price raised to HK$25.24 from HK$24.11, indicating a potential upside of 37.6% from the current price of HK$18.34 [3][20]. Core Insights - Hansoh Pharma has successfully out-licensed its oral GLP-1 drug candidate HS-10535 to MSD, receiving an upfront payment of US$112 million and potential milestone payments up to US$1.9 billion, along with future sales royalties [1]. - The company has a robust pipeline of GLP-1 assets, including Fulaimei, HS-20094, and HS-10501, with ongoing clinical trials that position it competitively in the global oral GLP-1 drug development race [1][18]. - The safety profile of oral GLP-1 drugs is a critical differentiating factor, with various candidates showing promising weight loss data and varying safety concerns [1]. Financial Summary - Revenue is projected to grow from RMB 10,104 million in FY23A to RMB 12,301 million in FY24E, reflecting a year-on-year growth of 21.7% [2][23]. - Net profit is expected to increase significantly from RMB 3,277.5 million in FY23A to RMB 4,382.9 million in FY24E, marking a growth of 33.7% [2][23]. - The earnings per share (EPS) is forecasted to rise from RMB 0.55 in FY23A to RMB 0.74 in FY24E, with a P/E ratio decreasing from 31.1x to 23.3x [2][23]. Pipeline Development - Hansoh's HS-20094, a GLP-1/GIP dual agonist, has initiated a Phase 3 obesity study in China, with Phase 2 trial results expected next year [1]. - The company is also advancing HS-10501 through Phase 1 trials, further expanding its GLP-1 drug portfolio [1]. - The collaboration with MSD is anticipated to accelerate the development of HS-10535 and unlock its global potential [1].

Summary of the Conference Call Company and Industry Overview - The conference call focused on **Hansen Pharmaceutical**, a leading player in the **innovative pharmaceutical industry** in China, with over 30 years of experience in the sector [3][4]. Key Points and Arguments Industry Outlook - The pharmaceutical sector is gradually recovering from a downturn experienced over the past two to three years, with expectations of improvement starting from Q4 2023 [1]. - Recent discussions have highlighted the positive direction of medical insurance negotiations and the encouragement of commercial insurance policies, which are expected to support the industry [1]. Company Performance - Hansen Pharmaceutical achieved a revenue of **10.104 billion CNY** in 2023, marking a **7.7%** increase year-over-year, with a net profit of **3.278 billion CNY**, a **26.85%** increase [7]. - In the first half of 2024, the company reported revenues of **6.506 billion CNY**, a **44.21%** increase, and a net profit of **2.726 billion CNY**, a **111.47%** increase, largely attributed to the recognition of revenue from two ADC products licensed to GSK [7]. Product Portfolio and Innovation - The company has successfully transitioned to an innovation-driven model, with over **60%** of its revenue coming from innovative drugs [4][11]. - Key products include **Amatinib**, the first domestically developed third-generation EGFR TKI, which has seen increasing market share and sales [5][15]. - The company is also focusing on expanding its pipeline, with **50 innovative drug products** currently in clinical research, including treatments for diabetes and autoimmune diseases [12][30]. Research and Development - Hansen has significantly increased its R&D investment from **9.3%** in 2017 to over **20%** in 2023, aligning with international standards for innovative drug companies [8]. - The company maintains a dual strategy of self-research and business development (BD), with successful collaborations leading to substantial licensing revenues [10][21]. Financial Projections and Valuation - The company is projected to maintain a revenue growth rate of over **20%** for its innovative drug products over the next five years, with expected revenues reaching **7.984 billion CNY**, **9.653 billion CNY**, and **11.641 billion CNY** by 2026 [34]. - The estimated fair value of Hansen Pharmaceutical is approximately **123 billion CNY**, translating to a target price of **22.27 HKD** per share [38]. Other Important Insights - The oncology segment remains a strong revenue driver, accounting for nearly **70%** of total income, while other therapeutic areas contribute around **10%** [8]. - The company is optimistic about the future growth of its hepatitis B treatment, **Amitin**, and its innovative diabetes treatment, which is expected to capture significant market share [22][28]. - The overall market for GLP-1 drugs is projected to exceed **7 billion CNY** in 2023, with Hansen's products positioned to gain a substantial share [28]. This summary encapsulates the key insights from the conference call regarding Hansen Pharmaceutical's performance, strategic direction, and market outlook.